PXMD PaxMedica
- 0.740
- +0.036+5.06%
- 0.730
- -0.010-1.32%
PaxMedica News
PaxMedica | 8-K: PaxMedica Responds to Emergency Request for IV Suramin and Commits to Provide Immediate Access to PAX-101
PaxMedica | 8-K: PaxMedica Receives Emergency Request for IV Suramin from African Health Ministry for Use in Treating Fatal Sleeping Sickness
PaxMedica | DEF 14A: Definitive information statements
PaxMedica | 8-K: PaxMedica Achieves Key Milestone in the Development of PAX-101 And Provides Update on Potential NDA Submission
PaxMedica | PRE 14A: Preliminary proxy statements relating to merger or acquisition
PaxMedica | 8-K: Current report
PaxMedica | 8-K: PaxMedica Releases Updated Company Profile Presentation
PaxMedica | 8-K: PaxMedica Board of Directors Announces Employee Restricted Stock Grants
PaxMedica | 8-K: Current report
PaxMedica | 8-K: The Company Has Demonstrated Compliance with Disclosures Related to the Minimum Shareholder Rights Requirements of Nasdaq Listing Rule 5550(B)(1)
PaxMedica | 8-K: Final Cash Payment of $0.2 Million of Outstanding Secured Convertible Promissory Note
PaxMedica | 8-K: Disclosure Information of Public Offering in Compliance With Nasdaq Listing Rule 5550(b)(1)
PaxMedica | 8-K: PaxMedica Announces Pricing of $7.0 Million Public Offering
PaxMedica | S-1/A: General form for registration of securities under the Securities Act of 1933 (Amendment)
PaxMedica | 8-K: PaxMedica, Inc. Announces Third Quarter 2023 Financial Results and Business Update
PaxMedica | 8-K: PaxMedica Has Demonstrated Compliance with Nasdaq Bid Price Requirement with Respect to the Common Stock
PaxMedica | NT 10-Q: Notice under Rule 12b25 of inability to timely file all or part of a form 10-Q or 10-QSB
PaxMedica | 8-K: Financial Condition for the Three Months Ended September 30, 2023 and Entry into a Securities Purchase Agreement
PaxMedica | S-1: General form for registration of securities under the Securities Act of 1933
PaxMedica | 8-K: Current report
Analysis
Price Target
No Data
